Free Newsletter
Push for translational medicine triggers shakeup
A group of academic research centers has reorganized around the NIH's $100 million program to encourage translational research, bringing scientists and clinicians together to advance therapies in clinical trials. The Scientist reports on the work of a variety of U.S. centers that are gearing up more early-stage research work into new cancer therapies. That means more support for the work to push therapies from research projects into the clinic, new facilities to manufacture experimental therapies and assistance in dealing with regulators. For drug developers, the new approach is expected to deliver a fresh set of promising experimental therapies. Wyeth, for example, reorganized its efforts around translational medicine last year. The new emphasis has significantly increased demand for research scientists experienced in translational research and spurred academic centers to offer more education on clinical trials. The NIH's goal is to have 60 centers operating in five years.
- read the article on translational research from The Scientist
Related Articles:
NIH budgets $71M to study rare diseases. Report
NIH program to create academic research consortium. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: